Person: İZZETTİN, FIKRET VEHBI
3 results
Search Results
Now showing 1 - 3 of 3
Publication Metadata only Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography(2022-01-01) OKUYAN B.; TOK F.; KARAKUŞ S.; Dalgiç N.; ÇAKIR E.; Midyat L.; Koçyiğit-Kaymakçioğlu B.; Berk U. E.; İZZETTİN F. V.; Rollas S.; et al.; ÇAKIR, ERKAN; İZZETTİN, FIKRET VEHBI© 2022 Marmara University Press.The aim of this study is to perform therapeutic drug monitoring for isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) in pediatric tuberculosis patients. The study was carried out in 3 different training-research hospitals in Istanbul, Türkiye between 2011 and 2012. The pediatric patients (aged ≤14 years) who initiated the standard primary anti-tuberculosis therapy were included in this study. The serum samples were collected 3 hours after the first medication doses were given on the 5th day of treatment. Chromatographic experiments were performed on an Agilent 1100 High-Performance Liquid Chromatography (HPLC) system, and the separation was carried out on a Nova-Pak C18 (3.9x150 mm, 5 μm, Merck) analytical column. In this HPLC method, the gradient elusion delivered 3% to 40% (v/v) acetonitrile in phosphate buffer was used, and diode array detector. Twenty-three children (60.9% male) patients were included with a mean age of 111.70 ± 59.94 months. Plasma levels were measured sub-therapeutically for INH in 14, RIF in 10, and PZA in 5 patients, according to the normal range of adult patients. Maximum plasma concentrations after three hours were found between 0.53-14.02 mg/L for INH, 11.17-60.39 mg/L for PZA, 2.15-16.75 mg/L for RIF. In conclusion, this method has been successfully applied to simultaneously determine RIF, INH, and PZA plasma levels in pediatric tuberculosis patients. RIF and INH plasma levels were found to be lower in pediatric patients with tuberculosis compared to target range of adult patients.Publication Open Access Identification of Drug-Related Problems and Investigation of Related Factors in Patients with COVID-19: An Observational Study(2022-12-01) Bektay M. Y.; Sancar M.; Okyaltırık F.; Durdu B.; İzzettin F. V.; BEKTAY, MUHAMMED YUNUS; OKYALTIRIK, FATMANUR; DURDU, BÜLENT; İZZETTİN, FIKRET VEHBIObjective: Clinical prognosis of coronavirus disease-19 (COVID-19) may be severe and unexpected. Patients may quickly progress to respiratory failure, infections, multiple organ dysfunction, and sepsis. The main objective of this study is to investigate the drug-related problems of patients with COVID-19 and related factors. Method: A prospective observational study was conducted on patients with COVID-19 between September 2020 and May 2021. Patients’ demographics, comorbid diseases, prescribed medicines and laboratory findings were recorded. Drug-related problems (DRPs) were identified by a clinical pharmacist according to recent guidelines, UpToDate® clinical decision support system and evidence-based medicine. Results: The median age of 107 patients was 64 and 50.46% of them were male. The median number of comorbidities was 3 (2-4) per patient. The majority of the patients had at least one comorbidity (88.79%) other than COVID-19 and the most frequent comorbidities were hypertension, diabetes mellitus and coronary artery disease. The total number of DRPs was recorded as 201 and at least one DRP was seen in 75 out of 107 patients. The median number of DRPs was 2 (0-8). In multivariate model, number of comorbidities (odss ratio (OR)=1.952; 95% confidence interval (CI)=1.07-3.54, p<0.05, number of medications (OR=1.344; 95% CI=1.12-1.61, p<0.001), and serum potassium levels (OR=5.252; 95% CI=1.57-17.56, p<0.001) were the factors related with DRP. Conclusion: This study highlights the DRPs and related factors in patients with COVID 19 in hospital settings. Considering unknown features of the infection and multiple medication use, DRPs are likely to occur. It would be beneficial to consider the related factors in order to reduce the number of the DRPs.Publication Metadata only Hipertansiyonda uyum ve hastalık algısına eczacı katkısının değerlendirilmesi: Gözlemsel bir çalışma(2023-09-01) Guruhan E.; Bektay M. Y.; Yılmaz Z.; İzzettin F. V.; BEKTAY, MUHAMMED YUNUS; İZZETTİN, FIKRET VEHBIAim: Hypertension (HT) is a chronic disease characterized by high blood pressure and can cause many complications. Pharmacists can contribute to the quality of life and treatment success of HT patients with their pharmaceutical care service. The aim of our study is to examine the effects of pharmaceutical care services provided by pharmacists on HT illness perceptions and treatment adherence.Methods: This study was a non-invasive, prospective, observational study with participation of HT patient who applied a community pharmacy in Istanbul between June-December 2020. In the first interview, demographic data, illness perceptions, and adherence levels of the participants were measured. At the end of the first interview, the participants were given structured written and oral training by the pharmacist, and the effects of the training provided by the pharmacist were measured again in the second interview 90 days later. The Illness Perception Questionnaire and the Morisky Green Levine Treatment Adherence Scale were used to examine the effects of the services provided by the pharmacist after two interviews conducted three months apart.Results: Of the 75 patients included in our study, 48, 64% were female, and the mean age was 59.68 ± 10.79 years. Most participants (55, 73.32%) had a secondary school education or less, and 58 (77.33%) were not working. In our sample, where the mean duration of HT was 11.48 ± 7.24 years, the most frequently prescribed antihypertensive drug group was diuretics. After the pharmaceutical care service provided by the pharmacist, a statistically significant difference was observed in all sub-dimensions of the participants\" illness perception (p<0.05). The adherence level of the participants increased from 79.75% to 95% after the pharmacist intervention, and this increase was statistically significant (p<0.05).Conclusion: It is available in the literature that increased disease perception and adherence in HT patients have positive effects on treatment success and quality of life. In our study, the effects of the pharmaceutical care service provided by the pharmacist were shown. As a result, clinical pharmacists are needed to improve patient care.